Aliment Pharmacol Ther 1993; 8: 661–668.

Index

24-h pH, 549
5-aminosalicylates, 35
5-aminosalicylic acid, 289
5-HT_3 agonists, 403
5-hydroxytryptamine, 461
Abbühl, B. *see* Hurlimann, S.
Abildgaard, K. *see* Christensen, L. A.
acetaminophen, 593
acetic acid, 433
acetraminophen, 315
acid inhibition, 579, 598
acid secretion, 95, 193
acid-related diseases, 81
acute hepatitis, 229
adaptation, 15
aetiology, 3
Ahlberg, J. *see* Bardhan, K. D.
AIDS, 347
Ainsworth, M. A. *see* Hogan, D. L.
Al-Assi, M. T., Genta, R. M. & Graham, D. Y., Short report: omeprazole–tetracycline combinations are inadequate as therapy for *Helicobacter pylori* infection, 259
Al-Assi, M. T., Genta, R. M., Karttunen, T. J. & Graham, D. Y., Clarithromycin–amoxycillin therapy for *Helicobacter pylori* infection, 453
Alpers, D. H. *see* Clouse, R. E.
aminopyrine breath test, 353
amoxycillin, 259, 495, 568
amoxycillin/omeprazole, 323
anaemia, 343
Anand, S. B., Torres, E., Operkun, A. & Graham, D. Y., Comparative assessment of phenolphtalein and phenolphtalein glucuronide: is phenolphthalein glucuronide a better laxative?, 559
Annibale, B., de Magistris, L., Corleto, V., D'Ambra, G., Marignani, M., Iannoni, C. & Delle Fave, G., Zollinger–Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease, 87
Annibale, B., Delle Fave, G., Azzoni, C., Corleto, V., Camboni, G., D'Ambra, G., Pilato, F. P. & Bordi, C., Three months of ocreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger–Ellison syndrome and antral G-cell hyperfunction, 95
Anreoli, A. *see* Caprilli, R.
antacid, 123
antagonist, 193
Anthony, A., Dhillon, A. P., Sim, R., Nygard, G., Pounder, R. E. & Wakefield, A. J., Ulceration, fibrosis and diaphragm-like lesions in the caecum of rats treated with indomethacin, 417
Anthony, A., Dhillon, A. P., Sim, R., Pounder, R. E. & Wakefield, A. J., Dexamethasone promotes ulcer plugging in experimental enteritis, 597
antibiotics, 359, 596
antidepressant therapy, 409
antimicrobial resistance, 359
antimicrobial therapy, 259, 568
antiviral therapy, 229
antral G-cell hyperplasia, 87
Applefeld, J. J., Kasmer, R. J., Hak, L. J., Dukes, G. E., Wermeling, D. P. & McClain, C. J., A dose–response study of orally administered torsemide in patients with ascites due to cirrhosis, 397
Ar'Rajab, A. *see* Fabia, R.
argyrophil cells, 95
argyrophilic cells, 541
Arienti, V., Corazza, G. R., Sorge, M., Boriani, L., Ugenti, F., Biagi, F., Maconi, G., Sottili, S., Van Thiel, D. H. & Gasbarrini, G., The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia, 631
ascites, 397
Ashraf, W., Lof, J., Jin, G. & Quigley, E. M. M., Comparative effects in intraduodenal psyllium and senna on canine small bowel motility, 329
aspirin, 141, 521
Assuero Lanfranchi, G. *see* Caprilli, R.
Atherton, J. C., Hudson, N., Kirk, G. E., Hawkey, C. K. & Spiller, R. C., Amoxycillin capsules with omeprazole for the eradication of *Helicobacter pylori*. Assessment of the importance of antibiotic dose timing in relation to meals, 495
Atherton, J. C., Washington, N., Bracewell, M. A., Sutton, L. J., Greaves, J. L., Perkins, A. C., Hawkey, C. J. & Spiller, R. C., Scintigraphic assessment of the intragastric distribution and gastric emptying of an encapsulated drug: the effect of feeding and of a proton pump inhibitor, 489
attachment, 187
Aukee, S. *see* Tarpila, S.
autoimmune chronic active hepatitis, 585
azithromycin, 187
Azzoni, C. *see* Annibale, B.

Babiuk, L. *see* Thomson, A. B. R.
Bachmann, K. A. *see* Sullivan, T. J.
bacteria, 597
Bakker, W. *see* Gan, K. H.
Barbara, L. *see* Belluzzi, A.
Barbara, L. *see* Bianchi Porro, G.
Barbara, L. *see* Brignola, C.
Barbara, L. *see* Gionchetti, P.

Bardhan, K. D., Ahlberg, J., Hislop, W. S., Lindholmer, C., Long, R. G., Morgan, A. G., Sjostedt, S., Smith, P. M., Stig, R., Wormsley, K. G., Langworthy, H. & Moules, I. K., Rapid healing of gastric ulcers with lansoprazole, 215
barostat, 403
Basilisco, G. & Phillips, S. F., A selective NK-2 antagonist blocks the increase of canine colonic tone and ileal contractions induced by the NK-2 selective receptor antagonist, [βAla^8] neurokinin A-(4–10), 527
Beattie, R. M., Schiffin, E. J., Donnet-Hughes, A., Hugget, A. C., Domizio, P., MacDonald, T. T. & Walker-Smith, J. A., Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease, 609
Belloli, C. *see* Brignola, C.
Belluzzi, A. *see* Brignola, C.
Belluzzi, A. *see* Gionchetti, P.
Belluzzi, A., Brignola, C., Campieri, M., Gionchetti, P., Rizzello, F., Boschi, S., Cunanne, S., Migioli, M. & Barbara, L., Short report: zinc sulphate supplementation corrects abnormal erythocyte membrane long-chain fatty acid composition in patients with Crohn's disease, 127
benzimidazoles, 187
Bereson, M. M. *see* Simon, T. J.
Berlin, R. G. *see* Simon, T. J.
Berry, M. A. & DiPalma, J. A., Review article: orthograde gut lavage for colonoscopy, 391
Berstad, A. *see* Berstad, K.
Berstad, K., Sjödahl, R. & Berstad, A., Phospholipase A_2 activity in gastric juice from patients with active and *H. pylori*-eradicated healed duodenal ulcer, 175
Bertrams, J. *see* Labenz, J.
Bethke, Th. *see* Damman, H. G.
Biagi, F. *see* Arienti, V.
Bianchi Porro, G., Corinaldesi, R., Lazzaroni, M., Barbara, L., Capurso, L., Paoluzi, P., Mangiameli, A., Sabbatini, F., Franceschi, M. & Bolling, E., Long term treatment with omeprazole 20 mg three days a week or 10 mg daily in the prevention of duodenal ulcer relapse, 541
bicarbonate, 475
Biemond, I. *see* Meijer, J. L.
Bigard, M. A. *see* Michel, P.
bile acid, 175
bioavailability, 55, 123, 289, 535
bismuth subsalicylate, 259
bismuth sucralfate, 351
bismuth, 45, 425, 469
bleeding, 141
Bolling, E. *see* Bianchi Porro, G.
Bommelaer, G. *see* Michel, P.
Bordi, C. *see* Annibale, B.
Borgä, O. *see* Nyman-Pantelidis, M.
Boriani, L. *see* Arienti, V.
Börsch, G. *see* Labenz, J.
Bosch, J., Bruix, J., Mas, A., Navasa, M. & Rodés, J., Rolling review: the treatment of major complications of cirrhosis, 639
Boschi, S. *see* Belluzzi, A.
Boschi, S. *see* Gionchetti, P.
Bouchier, I. A. D. *see* Plevris, J. N.
Bowes, K. *see* Thomson, A. B. R.
Bracewell, M. A. *see* Atherton, J. C.
bran, 511
Brattsand, R. *see* Fabia, R.
Brenard, R. *see* Horsmans, C. Y.
Brenna, E. *see* Waldum, H. L.
Brignola, C. *see* Belluzzi, A.
Brignola, C. *see* Gionchetti, P.
Brignola, C., De Simone, G., Belloli, C., Iannone, P., Belluzzi, A., Gionchetti, P., Campieri, M. & Barbara, L., Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration, 465
Brueton, M. J. *see* Pillai, G. V.
Bruix, J. *see* Bosch, J.
Bruley des Varannes, S. *see* Zerbib, F.
Bruley des Varannes, S., Levy, P., Lartigue, S., Dellatolas, F., Lemaire, M. & Galmiche, J. P., Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers, 309
budesonide, 433, 585, 591, 623, 617
Buéno, L. *see* Theodorou, V.
Burkhardt, F. *see* Damman, H. G.
Burnham, D. B., Miller, D., Karlstadt, R., Friedman, C. J. & Palmer, R. H., Famotidine increases plasma alcohol concentration in healthy subjects, 55
Burnham, W. R. *see* Tarpila, S.
Burroughs, A. K. *see* McCormick, P. A.
Burston, D. *see* Pillai, G. V.

caco-2 cells, 187
caecum, 417
Cagliola, A. *see* Simon, T. J.
Camboni, G. *see* Annibale, B.
Campieri, M. *see* Gionchetti, P.
Campieri, M. *see* Belluzzi, A.
Campieri, M. *see* Brignola, C.
Candida, 347
canine, 329
Capell, H. A. *see* Morris, A. J.
Caprilli, R., Anreoli, A., Capurso, L., Corrao, G., D'Albasio, G., Gioieni, A., Assuero Lanfranchi, G., Paladini, I., Pallone, F., Ponti, V., Rigo, G. P., Rossini, F. P., Sturniolo, G. C., Tonnelli, F., Valpiani, D. & The Gruppo Italiano per lo Studio del Colon e del Retto (GISC), Oral mesalaxine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease, 35
capsules, 27
Capurso, L. *see* Bianchi Porro, G.
Capurso, L. *see* Caprilli, R.
CC14, 315
cell proliferation, 167
Chaput, J. C. *see* Poynard, T.
children, 609
chlorine-containing phospholipids, 175

cholestasis, 337
Choudari, C. P., Elton, R. A. & Palmer, K. R., The outcome of peptic ulcer haemorrhage in relation to consumption of nonsteroidal anti-inflammatory drugs or asprin, 457
Christensen, L. A., Fallingborg, J., Jacobsen, B. A., Abildgaard, K., Rasmussen, H. H., Hansen, S. H. & Rasmussen, S. N., Comparative bioavailabilty of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation, 289
chronic hepatitis C, 353
chronic hepatitis, 229
chronic liver disease, 65
chronic pain, 409
cimetidine, 123, 147
cirrhosis, 397
cisapride, 147, 209
clarithromycin, 131, 469, 568
clinical features, 3
clinical trial, 259, 568
Clouse, R. E., Lustman, P. J., Geisman, R. A. & Alpers, D. H., Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience, 409
coffee, 283
Cole, A. T., Filipowicz, B., Hyman-Taylor, P. & Hawkey, C. J., Low dose aspirin: selective inhibition of rectal dialysis thromboxane B_2 in healthy voulnteers, 521
Colin, R. *see* Michel, P.
colitis, 433
colon cleansing, 391
colonic fluid secretion, 301
colonic tone, 527
colonic transit, 295
colonoscopy preparation, 209, 391
controlled release, 289
Corazza, G. R. *see* Arienti, V.
Corinaldesi, R. *see* Bianchi Porro, G.
Corleto, V. *see* Annibale, B.
Corrao, G. *see* Caprilli, R.
cortisol, 549, 591
Cowan, R. E. *see* Tarpila, S.
Crohn's disease, 127, 465, 609
Cuccurullo, F. *see* Neri, M.
Cunanne, S. *see* Belluzzi, A.
CYPIA induction, 593
cystic fibrosis, 603
cytochrome P-450, 353

D'Ambra, G. *see* Annibale, B.
D'Albasio, G. *see* Caprilli, R.
Damman, H. G., Bethke, Th., Burkhardt, F., Wolf, N., Khalil, H. & Luehmann, R., Effects of pantoprazole on endocrine function in healthy male volunteers, 549
Danielsson, Å. & Prytz, H., Oral budesonide for treatment of autoimmune chronic active hepatitis, 585
Danielsson, Å. *see* Löfberg, R.
Davies, J. M. *see* Plevris, J. N.
de Boer, W. A. & Tytgat, G. N. J., Review article: drug therapy for reflux oesophagitis, 147
de Koning, R. W. *see* Witteman, E. M.
De Korte, H. *see* Thijs, J. C.
de Magistris, L. *see* Annibale, B.
De Simone, G. *see* Brignola, C.
decaffeination, 283
Dellatolas, F. *see* Bruley des Varannes, S.
Delle Fave, G. *see* Annibale, B.
Dent, J. *see* Lobo, A. J.
dexamethasone, 597
Dhillon, A. P. *see* Anthony, A.
Dhillon, A. P. *see* Fraser, A. G.
Di Iorio, P. *see* Neri, M.
diagnosis and therapy, 3
diarrhoea, 3
Dick, R. *see* McCormick, P. A.
diet, 563
diosmectite, 295
dioxin receptor, 593
DiPalma, J. A. *see* Berry, M. A.
disease-specific parameters, 27
diuretic, 397
diverticular disease, 596
Dixon, J. S. *see* Simon, B.
Domizio, P. *see* Beattie, R. M.
Donnet-Hughes, A. *see* Beattie, R. M.
dose timing, 495
doses, 289
doxantrazole, 301
Droy-Lefaix, M. T. *see* Theodorou, V.
drug distribution, 489
drug therapy, 351, 563
drugs, 289
Duke, J. C. *see* Orr, W. C.
Dukes, G. E. *see* Applefeld, J. J.
duodenal ulcer disease, 175
duodenal ulcer, 81, 95, 135, 141, 259, 475, 541, 568
duodenum, 475
Dupas, J. L. *see* Michel, P.
Dupont, H. L., Review article: infectious diarrhoea, 3
Dusheiko, G. M., Rolling review—The management of viral hepatitis, 229
Dyal, R. *see* Nwokolo, C. U.
dyspepsia, 45

ECL cells, 95
elderly patients, 209
electromyography, 45
Elliot, R. *see* Plevris, J. N.
Elomaas, I. *see* Tarpila, S.
Elton, R. A. *see* Choudari, C. P.
endocrine function, 549
enema, 591, 617
enprostil, 221
epidemiology, 3
epigastric impedance, 631

epithelium, 475
eradication of H. Pylori, 167
eradication therapy, 369
eradication, 359
Erlansson, M. *see* Fabia, R.
ethanol, 55
ethyl alcohol, 315
Eyre-Brook, I. A. *see* Lobo, A. J.

Fabia, R., Ar'Rajab, A., Willén, R., Brattsand, R., Erlansson, M. & Svensjö, E., Topical anticolitic efficacy and selectivity of the glucocorticoid budesonide in a new model of acetic acid-induced acute colitis in the rat, 433
Fabia, R., Letter to the Editors, 659
faecal fat/protein balance studies, 603
Fallingborg, J. *see* Christensen, L. A.
famotidine, 55, 71, 123, 147
Farthing, M. J. G. *see* Gorard, D. A.
Farthing, M. J. G. *see* Katelaris, P. H.
Fenn, G. C., Review article: controversies in NSAID-induced gastroduodenal damage—do they matter?, 15
fibre, 596
fibrosis, 417
Filipowicz, B. *see* Cole, A. T.
Fioramonti, J. *see* Theodorou, V.
first variceal bleed, 65
Fitzpatrick, J. D. *see* Nwokolo, C. U.
fluconazole, 347
flumecinol, 337
Franceschi, M. *see* Bianchi Porro, G.
Fraser, A. G., Review article: gastro-oesophageal reflux and laryngeal symptoms, 265
Fraser, A. G., Sim, R., Sankey, E. A., Dhillon, A. P. & Pounder, R. E., Effect of eradication of *Helicobacter pylori* on gastric epithelial cell proliferation, 167
Friedman, C. J. *see* Burnham, D. B.
functional dyspepsia, 631

G-cell hyperfunction, 95
G-Wagner, Z. *see* Nyman-Pantelidis, M.
gall-bladder, 461
Galmiche, J. P. *see* Bruley des Varannes, S.
Galmiche, J. P. *see* Zerbib, F.
Gan, K. H., Heijerman, H. G. M., Geus, W. P., Bakker, W. & Lamers, C. B. H. W., Comparison of high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients, 603
Gasbarrini, G. *see* Arienti, V.
gastric acid secretion, 309
gastric acid, 425
gastric and gall-bladder emptying, 631
gastric compliance, 403
gastric mucosal injury, 141
gastric mucus, 181
gastric secretion, 87
gastric ulcer, 141, 215, 259, 568
gastril emptying, 489
gastrin cells, 541
gastrin processing, 515
gastrin, 87, 221, 515
gastritis, 167, 469
gastro-oesphageal reflux, 71, 283
gastroenteritis, 555
gastrointestinal absorption, 55
gastrointestinal implications, 15
Geisman, R. A. *see* Clouse, R. E.
general parameters, 27
Genta, R. M. *see* Al-Assi, M. T.
Germany, 135
Geubel, A. P. *see* Horsmans, C. Y.
Geus, W. P. *see* Gan, K. H.
Giardia lamblia, 187
Gioieni, A. *see* Caprilli, R.
Gionchetti, P. *see* Belluzzi, A.
Gionchetti, P. *see* Brignola, C.
Gionchetti, P., Campieri, M., Belluzzi, A., Boschi, S., Brignola, C., Migioli, M. & Barbara, L., Bioavailibility of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers, 535
glucomannan, 596
Gorard, D. A., Healy, J. C., O'Donnell, L. J. D. & Farthing, M. J. G., Inhibition of 5-hydroxytryptamine re-uptake impairs human gall-bladder emptying, 461
Gorard, D. A., Libby, G. W. & Farthing, M. J. G., Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome, 159
Graffner, H. *see* Löfberg, R.
Graham, D. Y. *see* Al-Assi, M. T.
Graham, D. Y. *see* Anand, S. B.
Gray, R. S. *see* Luman, W.
Greaves, J. L. *see* Atherton, J. C.
gut perfusion, 555
Gwee, K.-A. & Read, N. W., Rolling review: disorders of gastrointestinal motility—therapeutic potentials and limitations, 105

H^+, K^+-*ATPase*, 193
H^+-*activity*, 549
H. pylori, 175, 359
H_2-*blockers*, 81, 135
H_2-*receptor antagonist*, 55, 71
H_2-*receptor*, 193
haematemesis, 141
haemostasis, 141
Hak, L. J. *see* Applefeld, J. J.
Halter, F. & Ruchti, C., Letter to the Editors, 139
Halter, F. *see* Hurlimann, S.
Halvorsen, L. *see* Löfberg, R.
Hamilton, M. I. R. *see* Larner, A. J.
Hanauer, S. *see* Robinson, M.
Hansen, S. H. *see* Christensen, L. A.
Hawkey, C. J. *see* Atherton, J. C.
Hawkey, C. J. *see* Cole, A. T.

Hawkey, C. J., Review article: asprin and gastrointestinal bleeding, 141
Hawkey, C. K. *see* Atherton, J. C.
Hayes, P. C. *see* Plevris, J. N.
healing rates, 215
healthy male volunteers, 549
healthy subjects, 403
healthy volunteer, 521
Healy, J. C. *see* Gorard, D. A.
heartburn, 71
Heijerman, H. G. M. *see* Gan, K. H.
Heikius, B. *see* Tarpila, S.
Helicobacter eradication, 181
Helicobacter pylori, 131, 167, 259, 323, 351, 369, 489, 495, 469, 515, 568
high-lipase preparations, 603
Hine, K. R. *see* Tarpila, S.
Hislop, W. S. *see* Bardhan, K. D.
Hislop, W. S. *see* Plevris, J. N.
histamine, 425
Hogan, D. L., Ainsworth, M. A. & Isenberg, J. I., Review article: gastroduodenal bicarbonate secretion, 475
Hopman, W. P. M. *see* Witteman, E. M.
Horsmans, C. Y., Brenard, R. & Geubel, A. P., Short report: interferon-α decreases ^{14}C-aminopyrine breath test values in patients with chronic hepatitis, 353
Hovdenak, N. *see* Löfberg, R.
Hudson, N. *see* Atherton, J. C.
Hugget, A. C. *see* Beattie, R. M.
human, 521
Hurlimann, S., Abbühl, B., Inauen, W. & Halter, F., Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole, 193
hydrocortisone, 591
Hyman-Taylor, P. *see* Cole, A. T.

Iannone, P. *see* Brignola, C.
Iannoni, C. *see* Annibale, B.
Iishi, H. *see* Ueda, S.
Imes, N. K. *see* Orr, W. C.
imipramine, 159
Inauen, W. *see* Hurlimann, S.
indomethacin, 417, 597
infection, 579, 598
inflammatory bowel disease, 35
inhibitor tolerance, 193
interferon, 229, 353
interleukin-1 receptor antagonist protein (*rIRAP*), 301
intestinal anaphylaxis, 295, 301
intestinal permeability, 295
intestinal transit, 159
intragastric pH, 309
irritable bowel syndrome, 159, 409, 511
Isal, J. P. *see* Zerbib, F.
Isenberg, J. I. *see* Hogan, D. L.

Jacobsen, B. A. *see* Christensen, L. A.
James, O. F. W. *see* Turner, I. B.
Jansen, J. B. M. J. *see* Meijer, J. L.
Jansen, J. B. M. J. *see* Witteman, E. M.
Jauregui, L. *see* Sullivan, T. J.
jejunostomy, 563
Jin, G. *see* Ashraf, W.
Judmaier, G., Koelz, H. R. & Pantoprazole–Duodenal Ulcer Study Group, Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer, 81
Junien, J. L. *see* Theodorou, V.

Kääriäinen, I. *see* Tarpila, S.
Kaess, H. *see* Wendl, B.
Karlstadt, R. *see* Burnham, D. B.
Karttunen, T. J. *see* Al-Assi, M. T.
Karvonen, A.-L. *see* Tarpila, S.
Kasmer, R. J. *see* Applefeld, J. J.
Katelaris, P. H., Naeem, A. & Farthing, M. J. G., Activity of metronidazole, azithromycin and three benzimidazoles on *Giardia lamblia* growth and attachment to a human intestinal cell line, 187
Kerr, G. D., Letter to the Editors, 263
Khalil, H. *see* Damman, H. G.
Kirdeikis, P. *see* Thomson, A. B. R.
Kirk, G. E. *see* Atherton, J. C.
KN-2 agonist, 527
Koelz, H. R. *see* Judmaier, G.
Kuijpers, I. J. *see* Meijer, J. L.

Labenz, J., Ruhl, G. H., Bertrams, J. & Börsch, G., Effective treatment after failure of omeprazole plus amoxycillin to eradicate *Helicobacter pylori* infection in peptic ulcer disease, 323
Lamers, C. B. H. W. *see* Gan, K. H.
Lamers, C. B. H. W. *see* Meijer, J. L.
Langholz, E. *see* Löfberg, R.
Langworthy, H. *see* Bardhan, K. D.
lansoprazole, 147, 215, 309
Larner, A. J. & Hamilton, M. I. R., Review article: Infective complications of therapeutic gastric acid inhibition, 579
Lartigue, S. *see* Bruley des Varannes, S.
Laterza, F. *see* Neri, M.
laxative, 559
Lazzaroni, M. *see* Bianchi Porro, G.
Lemaire, M. *see* Bruley des Varannes, S.
Lemaire, M. *see* Michel, P.
Lennard-Jones, J. E., Review article: practical management of the short bowel, 563
Levine, L. *see* Sullivan, T. J.
levosulpiride, 631
Levy, P. *see* Bruley des Varannes, S.
Libby, G. W. *see* Gorard, D. A.
Lindholmer, C. *see* Bardhan, K. D.
liver injury, 315
Lobo, A. J., McNulty, C. A. M., Uff, J. S., Dent, J., Eyre-Brook, I. A. & Wilkinson, S. P., Preservation of gastric antral mucus is associated with failure of eradication of

Helicobacter pylori by bismuth, metronidazole and tetracycline, 181
local treatment, 585
Lof, J. *see* Ashraf, W.
Löfberg, R., Østergaard Thomsen, O., Langholz, E., Schiöler, R., Danielsson, Å., Suhr, O., Graffner, H., Pählman, L., Matzen, P., Møllerr-Peterson, J. F., Halvorsen, L., Hovdenak, N., Willén, R., Persson, T. & Seidegård, C., Budesonide versus prednisolone retention enemas in active distal ulcerative colitis, 623
Loft, D. E. *see* Nwokolo, C. U.
Long, R. G. *see* Bardhan, K. D.
long-chain fatty acids, 127
long-term therapy, 135
Luehmann, R. *see* Damman, H. G.
Luman, W., Gray, R. S., Pendek, R. & Palmer, K. R., Short report: Prednisolone metasulphobenzoate foam retention enemas suppress the hypothalamo-pituitary-adrenal axis, 255
Lustman, P. J. *see* Clouse, R. E.

MacDonald, T. T. *see* Beattie, R. M.
Mackenzie, J. F. *see* Morris, A. J.
Maconi, G. *see* Arienti, V.
Madhok, R. *see* Morris, A. J.
maintenance, 135
Mangiameli, A. *see* Bianchi Porro, G.
Marignani, M. *see* Annibale, B.
Marriage, B. *see* Thomson, A. B. R.
Mårvik, R. *see* Waldum, H. L.
Mas, A. *see* Bosch, J.
mast cells, 301
Matzen, P. *see* Löfberg, R.
McClain, C. J. *see* Applefeld, J. J.
McCormick, P. A., Dick, R. & Burroughs, A. K., Review article: the transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of portal hypertension, 273
McDonald, J. *see* Zerbib, F.
McNulty, C. A. M. *see* Lobo, A. J.
Meijer, J. L., Jansen, J. B. M. J., Biemond, I., Kuijpers, I. J. & Lamers, C. B. H. W., Effect of enprostil on serum gastrin and pepsinogen A and C levels in patients on long-term treatment with omeprazole, 221
melaena, 141
Mellow, M. H. *see* Orr, W. C.
mesalamine, 27
mesalazine, 289
metromidazole, 187
Mezzetti, A. *see* Neri, M.
Michael, S. *see* Simko, V.
Michel, P., Lemaire, M., Colin, R., Bommelaer, G., Rambaud, J. C., Dupas, J. L., Bigard, M. A. & Verwaerd, J. C., Short report: treatment of gastric ulcer with lansoprazole or ranitidine—a multicentre clinical trial, 119
microdissection, 167
Migioli, M. *see* Belluzzi, A.
Migioli, M. *see* Gionchetti, P.
Miller, D. *see* Burnham, D. B.
Miller, K. *see* Sullivan, T. J.
Mills, P. R. *see* Plevris, J. N.
misoprostol, 343
Møllerr-Peterson, J. F. *see* Löfberg, R.
Moolenaar, W. *see* Thijs, J. C.
Morgan, A. G. *see* Bardhan, K. D.
Morris, A. J., Murray, L., Sturrock, R. D., Madhok, R., Capell, H. A. & Mackenzie, J. F., Short report: the effect of misoprostol on the anaemia of NSAID enteropathy, 343
Mory, B. *see* Poynard, T.
motility, 329, 461
Moules, I. K. *see* Bardhan, K. D.
MRI, 45
mucus, 475
Muller, P. *see* Simon, B.
Murray, L. *see* Morris, A. J.
must cells, 301
myeloperoxidase activity, 433

Naeem, A. *see* Katelaris, P. H.
Navasa, M. *see* Bosch, J.
Naveau, S. *see* Poynard, T.
Neri, M., Susi, D., Laterza, F., Di Iorio, P., Seccia, G., Mezzetti, A. & Cuccurullo, F., Omeprazole, bismuth and clarithromycin in the sequential treatment of *Helicobacter pylori* infection, 469
neuroendocrine cells, 425
neuropsychological testing, 45
neurotoxicity, 45
new formulation 5-ASA, 535
Niemelä, S. *see* Tarpila, S.
Nilsson, Å. *see* Nyman-Pantelidis, M.
nizatidine, 123, 147
NK-2 agonist, 527
NK-2 antagonism, 527
Noach, L. A. *see* Reijers, M. H. E.
non-steroidal anti-inflammatory drugs, 343, 457
NSAIDs, 15
Nurmi, H. *see* Tarpila, S.
Nwokolo, C. U., Fitzpatrick, J. D., Paul, R., Dyal, R., Smits, B. J. & Loft, D. E., Lack of evidence of neurotoxicy following 8 weeks of treatment with tripotassium dicitrato dismuthate, 45
Nygard, G. *see* Anthony, A.
Nyman-Pantelidis, M., Nilsson, Å., G-Wagner, Z. & Borgä, O., Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis, 617

O'Donnell, L. J. D. *see* Gorard, D. A.
octreotide, 95
Oda, K. *see* Ueda, S.
oesophagitis, 71, 147, 347
olsalazine, 289
omeprazole metabolism, 593
omeprazole, 147, 193, 221, 259, 309, 469, 489, 495, 541

Oom, J. A. J. *see* Thijs, J. C.
Operkun, A. *see* Anand, S. B.
oral rehydration solutions, 555
Oriola, R. C. *see* Zerbib, F.
Orr, W. C., Duke, J. C., Imes, N. K. & Mellow, M. H., Comparative effects of H_2-receptor antagonists on subjective and objective assessments of sleep, 203
Osaka, S. *see* Ueda, S.
Østergaard Thomsen, O. *see* Löfberg, R.

Pählman, L. *see* Löfberg, R.
Paladini, I. *see* Caprilli, R.
Pallone, F. *see* Caprilli, R.
Palmer, K. R. *see* Choudari, C. P.
Palmer, K. R. *see* Luman, W.
Palmer, R. H. *see* Burnham, D. B.
pancreatic enzyme supplements, 603
pancreatic insufficiency, 603
Pantoprazole–Duodenal Ulcer Study Group *see* Judmaier, G.
pantoprazole, 81, 549
Paoluzi, P. *see* Bianchi Porro, G.
paroxetine, 159, 461
Paul, R. *see* Nwokolo, C. U.
PCNA, 167
PEG-ELS, 391
Pehl, C. *see* Wendl, B.
Pendek, R. *see* Luman, W.
Penston, J. G., Review article: *Helicobacter pylori* eradication—understandable caution but no excuse for inertia, 369
pentasa, 289
pepsinogen A and C, 221
peptic ulcer disease, 135
peptic ulcer haemorrage, 457
peptic ulcer, 369
Perkins, A. C. *see* Atherton, J. C.
permeability, 433
Persson, T. *see* Löfberg, R.
Persson, T. *see* Tarpila, S.
Pfeiffer, A. *see* Wendl, B.
pH monitoring, 309
pH, 175
pharmacokinetics, 617
phenolphthalein glucuronide, 559
phenolphthalein, 559
Phillips, S. F. *see* Basilisco, G.
phospholipase A_2, 175
Pikkarainen, P. *see* Tarpila, S.
Pilato, F. P. *see* Annibale, B.
Pillai, G. V., Brueton, M. J., Burston, D. & Sandhu, B. K., Studies of water movement across the gut using oral rehydration solutions in a rat perfusion model, 555
Plevris, J. N., Elliot, R., Mills, P. R., Hislop, W. S., Davies, J. M., Bouchier, I. A. D. & Hayes, P. C., Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease, 63
Plique, O. *see* Theodorou, V.
polymeric diet, 609
Ponti, V. *see* Caprilli, R.
Pounder, R. E. *see* Anthony, A.
Pounder, R. E. *see* Fraser, A. G.
Poynard, T., Naveau, S., Mory, B. & Chaput, J. C., Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, 499
prednisolone metasulphobenzoate, 255
primary biliary cirrhosis, 337
proliferating cell nuclear antigen, 167
propramolet, 65
prostaglandin E_2, 221
prostaglandins, 301
protitis, 591
proton pump inhibitor, 81, 309, 489, 495, 549
pruritus, 337
Prytz, H. *see* Danielsson, Å.
psylluim, 329

quality of life, 27
Quigley, E. M. M. *see* Ashraf, W.
Qvigstad, G. *see* Waldum, H. L.

Rambaud, J. C. *see* Michel, P.
ranitidine, 81, 123, 135, 147, 193, 215
Rasmussen, H. H. *see* Christensen, L. A.
Rasmussen, S. N. *see* Christensen, L. A.
rat, 315, 417, 433, 597
Rawlins, M. D. *see* Turner, I. B.
Read, N. W. *see* Gwee, K.-A.
real-time ultrasonography, 631
rectal dialysis, 521
Reijers, M. H. E., Noach, L. A. & Tytgat, G. N. J., Short report: evaluation of *Helicobacter pylori* eradication with bismuth sucralfate, 351
remission, 609
resistant duodenal ulcer, 87
Resse, J. H. *see* Sullivan, T. J.
retrograde spread, 617
rifaximin, 596
Rigo, G. P. *see* Caprilli, R.
Rizzello, F. *see* Belluzzi, A.
Robinson, M., Hanauer, S., Hoop, R., Zbrozek, A. & Wilkinson, C., Mesalamine capsules enhance the quality of life for patients with ulcerative colitis, 27
Rodés, J. *see* Bosch, J.
Rossini, F. P. *see* Caprilli, R.
roxatidine, 147
Ruchti, C. *see* Halter, F.
Ruhl, G. H. *see* Labenz, J.
Ruhnaar, E. A. *see* Thijs, J. C.

Sabbatini, F. *see* Bianchi Porro, G.
Salde, L. *see* Tarpila, S.
Sandhu, B. K. *see* Pillai, G. V.
Sandvik, A. K. *see* Waldum, H. L.
Sankey, E. A. *see* Fraser, A. G.

Schiffrin, E. J. *see* Beattie, R. M.
Schiöler, R. *see* Löfberg, R.
Schmidt, T. *see* Wendl, B.
Schutz, E. *see* Simon, B.
scintigraphy, 489
Scott, L. D. & Sellin, J. H., Letter to the Editors, 473
Seccia, G. *see* Neri, M.
Seidegård, C. *see* Löfberg, R.
Sellin, J. H. *see* Scott, L. D.
senna, 329
Seppälä, K. *see* Tarpila, S.
serum gastrin, 541
Shepherd, H. A. *see* Snook, J.
short gut, 563
Sim, R. *see* Anthony, A.
Sim, R. *see* Fraser, A. G.
Simko, V. & Michael, S., Effect of ursodeoxycholic acid on *in vivo* and *in vitro* toxic liver injury in rats, 315
Simon, B., Schutz, E., Muller, P. & Dixon, J. S., Short report: long-term management of peptic ulcer disease with rantidine in Germany, 135
Simon, T. J., Bereson, M. M., Berlin, R. G., Snapinn, S. & Cagliola, A., Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis, 71
Sipponen, P. *see* Tarpila, S.
Sjödahl, R. *see* Berstad, K.
Sjostedt, S. *see* Bardhan, K. D.
small bowel enteropathy, 343
small bowel, 329
Smith, P. M. *see* Bardhan, K. D.
Smits, B. J. *see* Nwokolo, C. U.
Snapinn, S. *see* Simon, T. J.
Snook, J. & Shepherd, H. A., Bran supplementation in the treatment of irritable bowel syndrome, 511
somatosatin, 425
Sorge, M. *see* Arienti, V.
Sottili, S. *see* Arienti, V.
Spiller, R. C. *see* Atherton, J. C.
spironolactone, 397
steroid-dependence, 465
steroids, 465
Stig, R. *see* Bardhan, K. D.
stomach, 475, 489, 495
Sturniolo, G. C. *see* Caprilli, R.
Sturrock, R. D. *see* Morris, A. J.
sucralfate, 147
Suhr, O. *see* Löfberg, R.
Sullivan, T. J., Resse, J. H., Jauregui, L., Miller, K., Levine, L. & Bachmann, K. A., Short report: a comparative study of the interaction between antacid and H_2-receptor antagonists, 123
survival, 65
Susi, D. *see* Neri, M.
Sutton, L. J. *see* Atherton, J. C.
Svensjö, E. *see* Fabia, R.
symptom relief, 215
Syversen, U. *see* Waldum, H. L.

Tarpila, S., Turunen, U., Seppälä, K., Aukee, S., Pikkarainen, P., Elomaas, I., Karvonen, A.-L., Kääriäinen, I., Sipponen, P., Toivanen, E., Heikius, B., Niemelä, S., Nurmi, H., Tunturihihnala, H., Burnham, W. R., Cowan, R. E., Hine, K. R., Persson, T. & Salde, L., Budesonide enema in active haemorrhagic proctitis—a controlled trial against hydrocortisone foam enema, 591
Tatsuta, M. *see* Ueda, S.
tea, 283
testosterone, 549
tetracycline, 259
The Gruppo Italiano per lo Studio del Colon e del Retto (GISC) *see* Caprilli, R.
Theodorou, V., Fioramonti, J., Droy-Lefaix, M. T., Plique, O. & Buéno, L., Protective action of diosmectite treatment on digestive disturbances induced by intestinal anaphylaxis in the guinea-pig, 295
Theodorou, V., Fioramonti, J., Junien, J. L. & Buéno, L., Anaphylactic colonic hypersecretion in cow's milk sensitized guinea-pigs depends upon release of Interleukin-1, prostaglandins and mast cell degranulation, 301
therapy, 147
Thijs, J. C., Van Zwet, A. A., Moolenaar, W., Oom, J. A. J., De Korte, H. & Ruhnaar, E. A., Short report: clarithromycin, an alternative to metronidazole in the triple therapy of *Heliobacter pylori* infection, 131
Thomson, A. B. R., Babiuk, L., Kirdeikis, P., Zuk, L., Marriage, B. & Bowes, K., A dose-ranging study of rantidine and its effect on intragastric and intra-oesophageal acidity in subjects with gastro-oesophageal reflux disease, 443
thromboxane, 521
Toivanen, E. *see* Tarpila, S.
Tonnelli, F. *see* Caprilli, R.
topical treatment, 623
Torres, E. *see* Anand, S. B.
torsemide, 397
treatment, 35
triple therapy, 131, 323
Tunturihihnala, H. *see* Tarpila, S.
Turner, I. B., Rawlins, M. D., Wood, P. & James, O. F. W., Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis, 337
Turunen, U. *see* Tarpila, S.
Tytgat, G. N. J. *see* de Boer, W. A
Tytgat, G. N. J. *see* Reijers, M. H. E.
Tytgat, G. N. J., Review article: treatments that impact favourably upon the eradication of *Helicobacter pylori* and ulcer recurrence, 359

Ueda, S., Iishi, H., Tatsuta, M., Oda, K. & Osaka, S., Addition of cisapride shortens colonoscopy preparation with lavage in elderly patients, 209
Uff, J. S. *see* Lobo, A. J.
Ugenti, F. *see* Arienti, V.

ulcer complication, 135
ulcer disease, 323
ulceration, 417
ulcerative colitis, 27, 623
ulcerative proctitis, 255
ursodeoxycholic acid, 315

Van Thiel, D. H. *see* Arienti, V.
Van Zwet, A. A. *see* Thijs, J. C.
Verhulst, M. L. *see* Witteman, E. M.
Verwaerd, J. C. *see* Michel, P.
viral hepatitis, 229
visceral perception, 403
visual evoked response, 45

Wakefield, A. J. *see* Anthony, A.
Waldum, H. L., Qvigstad, G., Mårvik, R., Brenna, E., Syversen, U. & Sandvik, A. K., The effect of tripotassium dictrato bismuthate on the rat stomach, 425
Walker-Smith, J. A. *see* Beattie, R. M.
Warren, B. F., Letter to the Editors, 659
Washington, N. *see* Atherton, J. C.
water absorption, 295
Wendl, B., Pfeiffer, A., Pehl, C., Schmidt, T. & Kaess, H., Effect of decaffeination of coffee or tea on gastro-oesophageal reflux, 283
Wermeling, D. P. *see* Applefeld, J. J.
Wilcox, C. M., Short report: time course of clinical response with fluconazole for *Candida* oesophagitis in patients with AIDS, 347
Wilkinson, C. *see* Robinson, M.
Wilkinson, S. P. *see* Lobo, A. J.
Willén, R. *see* Fabia, R.
Willén, R. *see* Löfberg, R.
Witteman, E. M., Verhulst, M. L., de Koning, R. W., Hopman, W. P. M. & Jansen, J. B. M. J., Basal serum gastrin concentrations before and after eradication of *Helicobacter pylori* infection measured by sequence specific radioimmunoassays, 515
Wolf, N. *see* Damman, H. G.
Wood, P. *see* Turner, I. B.
Wormsley, K. G. *see* Bardhan, K. D.

Zbrozek, A. *see* Robinson, M.
Zerbib, F., Bruley des Varannes, S., Oriola, R. C., McDonald, J., Isal, J. P. & Galmiche, J. P., Alosetron does not affect the visceral perception of gastric distension in healthy subjects, 403
zinc, 127
Zollinger–Ellison syndrome, 87, 95
Zuk, L. *see* Thomson, A. B. R.